ABBV logo

AbbVie (ABBV) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

02 January 2013

Indexes:

Description:

AbbVie Inc. is a global research-based biopharmaceutical company established in 2013 after separating from Abbott Laboratories. The headquarters are located in North Chicago, Illinois. AbbVie develops and promotes advanced treatments for some of the most complex and serious diseases in the world: chronic autoimmune diseases; oncology; virology, including hepatitis C virus and human immunodeficiency virus (HIV); Parkinson's disease; metabolic diseases (thyroid diseases and complications from cystic fibrosis) and others. All of the company's products meet industry standards and have patent protection.

Key Details

Price

$181.00

TTM Dividend Yield

3.43%(-8.53% YoY)

PE Ratio

62.85(+8.59% YoY)

Beta

0.25

Events Calendar

Earnings

Next earnings date:

Jan 31, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Feb 02, 2024
Dividend

Next ex-dividend date:

Jan 15, 2025

Recent ex-dividend date:

Oct 15, 2024
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

17 Dec '24 Piper Sandler
Overweight
22 Nov '24 Leerink Partners
Outperform
15 Nov '24 Wolfe Research
Outperform
13 Nov '24 JP Morgan
Overweight
12 Nov '24 Morgan Stanley
Overweight
12 Nov '24 Citigroup
Buy
12 Nov '24 BMO Capital
Outperform
06 Nov '24 Guggenheim
Buy
04 Nov '24 Argus Research
Buy
31 Oct '24 UBS
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
ABBV
Zacks03 January 2025

This Analyst Blog features companies like Eli Lilly, Johnson & Johnson, AbbVie, AstraZeneca, and Pfizer.

AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
ABBV
prnewswire.com03 January 2025

NORTH CHICAGO, Ill., Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) is set to release its financial results for the entire year and the fourth quarter of 2024 on Friday, January 31, 2025, before the market opens.

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
ABBV
benzinga.com03 January 2025

In periods of market instability and uncertainty, many investors seek out stocks that pay dividends. These stocks usually belong to companies with strong cash flows that provide generous dividends to their shareholders.

The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
ABBV
zacks.com03 January 2025

This Analyst Blog features companies like Eli Lilly, Johnson & Johnson, AbbVie, AstraZeneca, and Pfizer.

AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock?
AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock?
AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock?
ABBV
zacks.com31 December 2024

AbbVie (ABBV) could see an increase in its stock price due to rising confidence in its earnings potential, as shown by its upgrade to a Zacks Rank #2 (Buy).

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
ABBV
zacks.com31 December 2024

Lately, users of Zacks.com have been focusing on AbbVie (ABBV). Therefore, it's important to take a look at what this stock might offer.

Highest Quality Dividend Kings For 2025
Highest Quality Dividend Kings For 2025
Highest Quality Dividend Kings For 2025
ABBV
seekingalpha.com30 December 2024

In the past ten years, only 11 Dividend Kings have done better than the S&P 500 in terms of Total Return. According to my unique quantitative model, 5 of these Dividend Kings are considered "High Quality." By using a modified quality score, it could have resulted in a total return that was almost twice as much as the S&P 500 over the last 9 years.

The Smartest Dividend Stocks to Buy With $1,000 Right Now
The Smartest Dividend Stocks to Buy With $1,000 Right Now
The Smartest Dividend Stocks to Buy With $1,000 Right Now
ABBV
fool.com26 December 2024

If you're interested in stocks that pay good dividends, that's a wise choice. If you aren't considering them, you might want to think again, because:

AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing
AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing
AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing
ABBV
zacks.com24 December 2024

In the most recent trading session, AbbVie (ABBV) finished at $180, which is an increase of 0.9% compared to the day before.

Why AbbVie Inc. (ABBV) Is Among the Best Stocks to Buy and Hold for 3 Years?
Why AbbVie Inc. (ABBV) Is Among the Best Stocks to Buy and Hold for 3 Years?
Why AbbVie Inc. (ABBV) Is Among the Best Stocks to Buy and Hold for 3 Years?
ABBV
Insider Monkey24 December 2024

We have just released a list of the 10 Best Stocks to Buy and Hold for the Next 3 Years. In this article, we will examine how AbbVie Inc. (NYSE:ABBV) compares to the other top stocks on this list. What can we anticipate from the stock market in 2025?

FAQ

  • What is the primary business of AbbVie?
  • What is the ticker symbol for AbbVie?
  • Does AbbVie pay dividends?
  • What sector is AbbVie in?
  • What industry is AbbVie in?
  • What country is AbbVie based in?
  • When did AbbVie go public?
  • Is AbbVie in the S&P 500?
  • Is AbbVie in the NASDAQ 100?
  • Is AbbVie in the Dow Jones?
  • When was AbbVie's last earnings report?
  • When does AbbVie report earnings?
  • Should I buy AbbVie stock now?

What is the primary business of AbbVie?

AbbVie Inc. is a global research-based biopharmaceutical company established in 2013 after separating from Abbott Laboratories. The headquarters are located in North Chicago, Illinois. AbbVie develops and promotes advanced treatments for some of the most complex and serious diseases in the world: chronic autoimmune diseases; oncology; virology, including hepatitis C virus and human immunodeficiency virus (HIV); Parkinson's disease; metabolic diseases (thyroid diseases and complications from cystic fibrosis) and others. All of the company's products meet industry standards and have patent protection.

What is the ticker symbol for AbbVie?

The ticker symbol for AbbVie is NYSE:ABBV

Does AbbVie pay dividends?

Yes, AbbVie pays dividends. The last payment was $1.55, with an ex-dividend date on 15 October 2024

What sector is AbbVie in?

AbbVie is in the Healthcare sector

What industry is AbbVie in?

AbbVie is in the Drug Manufacturers - General industry

What country is AbbVie based in?

AbbVie is headquartered in United States

When did AbbVie go public?

AbbVie's initial public offering (IPO) was on 02 January 2013

Is AbbVie in the S&P 500?

Yes, AbbVie is included in the S&P 500 index

Is AbbVie in the NASDAQ 100?

No, AbbVie is not included in the NASDAQ 100 index

Is AbbVie in the Dow Jones?

No, AbbVie is not included in the Dow Jones index

When was AbbVie's last earnings report?

AbbVie's most recent earnings report was on 30 October 2024

When does AbbVie report earnings?

The next expected earnings date for AbbVie is 31 January 2025

Should I buy AbbVie stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions